EWTX Stock Summary and Trading Ideas (Edgewise Therapeutics | NASDAQ:EWTX)

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Edgewise Therapeutics trades on the NASDAQ stock market under the symbol EWTX.

As of April 15, 2026, EWTX stock price climbed to $33.70 with 1,137,619 million shares trading.

EWTX has a beta of 0.39, meaning it tends to be less sensitive to market movements. EWTX has a correlation of 0.01 to the broad based SPY ETF.

EWTX has a market cap of $3.57 billion. This is considered a Mid Cap stock.

In the last 3 years, EWTX traded as high as $38.12 and as low as $5.12.

The top ETF exchange traded funds that EWTX belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWO.

EWTX has outperformed the market in the last year with a return of +173.3%, while the SPY ETF gained +31.2%. In the last 3 month period, EWTX beat the market returning +19.6%, while SPY returned +1.6%. However, in the most recent 2 weeks EWTX has underperformed the stock market by returning +7.0%, while SPY returned +7.6%.

EWTX support price is $32.16 and resistance is $34.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EWTX shares will trade within this expected range on the day.